JP2008524261A - インフルエンザウイルスタンパク質の組成物およびその使用方法 - Google Patents

インフルエンザウイルスタンパク質の組成物およびその使用方法 Download PDF

Info

Publication number
JP2008524261A
JP2008524261A JP2007547054A JP2007547054A JP2008524261A JP 2008524261 A JP2008524261 A JP 2008524261A JP 2007547054 A JP2007547054 A JP 2007547054A JP 2007547054 A JP2007547054 A JP 2007547054A JP 2008524261 A JP2008524261 A JP 2008524261A
Authority
JP
Japan
Prior art keywords
protein
influenza
seq
composition
pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007547054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524261A5 (https=
Inventor
パウエル，トーマス，ジェイ．
ナカール，バレリアン
ソン，ランチョウ
マクドナルド，ウィリアム，エフ．
ヒューイット，デュアン，ディー．
Original Assignee
バクシネート コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクシネート コーポレーション filed Critical バクシネート コーポレーション
Publication of JP2008524261A publication Critical patent/JP2008524261A/ja
Publication of JP2008524261A5 publication Critical patent/JP2008524261A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007547054A 2004-12-21 2005-12-21 インフルエンザウイルスタンパク質の組成物およびその使用方法 Pending JP2008524261A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US63835004P 2004-12-21 2004-12-21
US63825404P 2004-12-21 2004-12-21
US64506705P 2005-01-19 2005-01-19
US65320705P 2005-02-15 2005-02-15
US66687805P 2005-03-31 2005-03-31
US68207705P 2005-05-18 2005-05-18
US74120205P 2005-11-30 2005-11-30
PCT/US2005/046662 WO2006069262A2 (en) 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2008524261A true JP2008524261A (ja) 2008-07-10
JP2008524261A5 JP2008524261A5 (https=) 2009-02-12

Family

ID=36272492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007547054A Pending JP2008524261A (ja) 2004-12-21 2005-12-21 インフルエンザウイルスタンパク質の組成物およびその使用方法

Country Status (9)

Country Link
EP (1) EP1831259A2 (https=)
JP (1) JP2008524261A (https=)
AU (2) AU2005319141B8 (https=)
BR (1) BRPI0519705A2 (https=)
CA (1) CA2593746A1 (https=)
MX (1) MX2007007586A (https=)
NZ (1) NZ556004A (https=)
SG (1) SG160424A1 (https=)
WO (1) WO2006069262A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516469A (ja) * 2010-01-06 2013-05-13 ヴァクシネイト コーポレイション 高齢者に保護免疫を提供するための方法及び組成物
JP2013523096A (ja) * 2010-03-26 2013-06-17 エマージェント プロダクト デベロップメント ゲイザーズバーグ インコーポレイテッド インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用
JP2013527218A (ja) * 2010-06-03 2013-06-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗原およびＴｏｌｌ様受容体アゴニストを含有する経口ワクチン

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
EP2374474A1 (en) * 2005-01-19 2011-10-12 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
US20100068224A1 (en) * 2006-04-24 2010-03-18 Roberto Crea Method for Producing Viral Vaccine and Therapeutic Peptide Antigens
PL2066339T3 (pl) * 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8778847B2 (en) * 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
EA017887B1 (ru) 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
GB0720250D0 (en) * 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
WO2009062348A1 (en) 2007-11-14 2009-05-22 Institute Of Microbiology, Chinese Academy Of Sciences Methods for inhibiting influenza virus infection and their drugs
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
MX348663B (es) * 2009-09-08 2017-05-26 Inst Tecnologico Estudios Superiores Monterrey Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
HK1208355A1 (en) * 2012-11-05 2016-03-04 Georgia State University Research Foundation, Inc. Universal influenza vaccine based on heterologous multiple m2e proteins
RU2571944C1 (ru) * 2014-10-17 2015-12-27 Общество с ограниченной ответственностью "НТфарма" Противогриппозная вакцина широкого спектра действия против птичьего гриппа а на основе эктодомена белка м2
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
WO2023028661A1 (en) * 2021-09-02 2023-03-09 Ena Respiratory Pty Ltd Formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014956A1 (en) * 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
WO2004080403A2 (en) * 2003-03-07 2004-09-23 Merck & Co. Inc. Influenza virus vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014956A1 (en) * 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
WO2004080403A2 (en) * 2003-03-07 2004-09-23 Merck & Co. Inc. Influenza virus vaccine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516469A (ja) * 2010-01-06 2013-05-13 ヴァクシネイト コーポレイション 高齢者に保護免疫を提供するための方法及び組成物
JP2013523096A (ja) * 2010-03-26 2013-06-17 エマージェント プロダクト デベロップメント ゲイザーズバーグ インコーポレイテッド インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用
JP2013527218A (ja) * 2010-06-03 2013-06-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗原およびＴｏｌｌ様受容体アゴニストを含有する経口ワクチン

Also Published As

Publication number Publication date
BRPI0519705A2 (pt) 2009-03-10
NZ556004A (en) 2010-05-28
AU2005319141A1 (en) 2006-06-29
AU2005319141B8 (en) 2010-03-18
SG160424A1 (en) 2010-04-29
MX2007007586A (es) 2007-12-10
EP1831259A2 (en) 2007-09-12
WO2006069262A3 (en) 2007-02-01
CA2593746A1 (en) 2006-06-29
AU2010200048A1 (en) 2010-01-28
WO2006069262A2 (en) 2006-06-29
AU2005319141B2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
JP2008524261A (ja) インフルエンザウイルスタンパク質の組成物およびその使用方法
JP6826027B2 (ja) インフルエンザ抗原送達用のベクターおよび構築体
US9511134B2 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
KR101983989B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
Kim et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection
ES2534332T3 (es) Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US20090162400A1 (en) Compositions of influenza viral proteins and methods of use thereof
CN103747797B (zh) 脂质体制剂
JP5775451B2 (ja) インフルエンザを処置するための組成物および方法
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
CN106661091B (zh) 流行性感冒病毒疫苗及其用途
CN107074912A (zh) 流行性感冒病毒疫苗及其用途
Sui et al. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant
US9963490B2 (en) Influenza nucleoprotein vaccines
JP2009528305A (ja) 鳥インフルエンザウイルスに対するキメラワクチン抗原
US12397050B2 (en) Universal mammalian influenza vaccine
US10286062B2 (en) Universal influenza vaccine
US20240366747A1 (en) Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
Kim et al. Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate
Mu et al. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA)
JP2018052953A (ja) インフルエンザウイルスワクチンおよびその使用
CN101087808A (zh) 流行性感冒病毒蛋白质的组合物及其使用方法
JP7167088B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP2026509251A (ja) インフルエンザｈ３ウイルスの広域反応性免疫原、その組成物および使用方法
Thueng-in Production of a prototype broad spectrum influenza a vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120413